213 related articles for article (PubMed ID: 35727633)
1. Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer.
Huang H; Nie CP; Liu XF; Song B; Yue JH; Xu JX; He J; Li K; Feng YL; Wan T; Zheng M; Zhang YN; Ye WJ; Li JD; Li YF; Li JY; Cao XP; Liu ZM; Zhang XS; Liu Q; Zhang X; Liu JH; Li J
J Clin Invest; 2022 Aug; 132(15):. PubMed ID: 35727633
[TBL] [Abstract][Full Text] [Related]
2. A phase II randomised controlled trial of adjuvant tumour-infiltrating lymphocytes for pretreatment Epstein-Barr virus DNA-selected high-risk nasopharyngeal carcinoma patients.
Liang YJ; Chen QY; Xu JX; Liu XF; Xia JC; Liu LT; Guo SS; Song B; Wang P; Li JB; Liu Q; Mo HY; Guo L; Sun R; Luo DH; He J; Liu YN; Nie CP; Tang LQ; Li J; Mai HQ
Eur J Cancer; 2023 Sep; 191():112965. PubMed ID: 37540921
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.
Li J; Chen QY; He J; Li ZL; Tang XF; Chen SP; Xie CM; Li YQ; Huang LX; Ye SB; Ke M; Tang LQ; Liu H; Zhang L; Guo SS; Xia JC; Zhang XS; Zheng LM; Guo X; Qian CN; Mai HQ; Zeng YX
Oncoimmunology; 2015 Feb; 4(2):e976507. PubMed ID: 25949875
[TBL] [Abstract][Full Text] [Related]
4. Tumor-infiltrating lymphocytes predict survival outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy.
Ohno A; Iwata T; Katoh Y; Taniguchi S; Tanaka K; Nishio H; Nakamura M; Morisada T; Chen G; Saito M; Yaguchi T; Kawakami Y; Aoki D
Gynecol Oncol; 2020 Nov; 159(2):329-334. PubMed ID: 32829964
[TBL] [Abstract][Full Text] [Related]
5. Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
Pillai M; Jiang Y; Lorigan PC; Thistlethwaite FC; Thomas M; Kirillova N; Bridgeman JS; Kueberuwa G; Biswas S; Velazquez P; Chonzi D; Guest RD; Roberts ZJ; Hawkins RE
Am J Cancer Res; 2022; 12(8):3967-3984. PubMed ID: 36119832
[TBL] [Abstract][Full Text] [Related]
6. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
[TBL] [Abstract][Full Text] [Related]
7. PD-L1 expression is associated with tumor infiltrating lymphocytes that predict response to NACT in squamous cell cervical cancer.
D'Alessandris N; Palaia I; Pernazza A; Tomao F; Di Pinto A; Musacchio L; Leopizzi M; Di Maio V; Pecorella I; Benedetti Panici P; Della Rocca C
Virchows Arch; 2021 Mar; 478(3):517-525. PubMed ID: 32915266
[TBL] [Abstract][Full Text] [Related]
8. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
Dudley ME; Gross CA; Somerville RP; Hong Y; Schaub NP; Rosati SF; White DE; Nathan D; Restifo NP; Steinberg SM; Wunderlich JR; Kammula US; Sherry RM; Yang JC; Phan GQ; Hughes MS; Laurencot CM; Rosenberg SA
J Clin Oncol; 2013 Jun; 31(17):2152-9. PubMed ID: 23650429
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Outcomes and Sites of Failure in Locally Advanced, Cervical Cancer Patients Treated by Concurrent Chemoradiation with or without Adjuvant Chemotherapy: ACTLACC Trial.
Tovanabutra C; Asakij T; Rongsriyam K; Tangjitgamol S; Tharavichitkul E; Sukhaboon J; Kridakara LCA; Paengchit K; Khunnarong J; Atjimakul T; Pariyawateekul P; Tanprasert P; Tungkasamit T; Lorvidhaya V
Asian Pac J Cancer Prev; 2021 Sep; 22(9):2977-2985. PubMed ID: 34582670
[TBL] [Abstract][Full Text] [Related]
10. The Dynamic Alternation of Local and Systemic Tumor Immune Microenvironment During Concurrent Chemoradiotherapy of Cervical Cancer: A Prospective Clinical Trial.
Li R; Liu Y; Yin R; Yin L; Li K; Sun C; Zhou Z; Li P; Tong R; Xue J; Lu Y
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1432-1441. PubMed ID: 33713744
[TBL] [Abstract][Full Text] [Related]
11. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango?
Kazemi MH; Sadri M; Najafi A; Rahimi A; Baghernejadan Z; Khorramdelazad H; Falak R
Front Immunol; 2022; 13():1018962. PubMed ID: 36389779
[TBL] [Abstract][Full Text] [Related]
12. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
[TBL] [Abstract][Full Text] [Related]
13. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
van den Berg JH; Heemskerk B; van Rooij N; Gomez-Eerland R; Michels S; van Zon M; de Boer R; Bakker NAM; Jorritsma-Smit A; van Buuren MM; Kvistborg P; Spits H; Schotte R; Mallo H; Karger M; van der Hage JA; Wouters MWJM; Pronk LM; Geukes Foppen MH; Blank CU; Beijnen JH; Nuijen B; Schumacher TN; Haanen JBAG
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753545
[TBL] [Abstract][Full Text] [Related]
14. Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancer.
Kokka F; Bryant A; Brockbank E; Powell M; Oram D
Cochrane Database Syst Rev; 2015 Apr; (4):CD010260. PubMed ID: 25847525
[TBL] [Abstract][Full Text] [Related]
15. Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Kverneland AH; Chamberlain CA; Borch TH; Nielsen M; Mørk SK; Kjeldsen JW; Lorentzen CL; Jørgensen LP; Riis LB; Yde CW; Met Ö; Donia M; Svane IM
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34607899
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
Tangjitgamol S; Tharavichitkul E; Tovanabutra C; Rongsriyam K; Asakij T; Paengchit K; Sukhaboon J; Penpattanagul S; Kridakara A; Hanprasertpong J; Chomprasert K; Wanglikitkoon S; Atjimakul T; Pariyawateekul P; Katanyoo K; Tanprasert P; Janweerachai W; Sangthawan D; Khunnarong J; Chottetanaprasith T; Supawattanabodee B; Lertsanguansinchai P; Srisomboon J; Isaranuwatchai W; Lorvidhaya V
J Gynecol Oncol; 2019 Jul; 30(4):e82. PubMed ID: 31074236
[TBL] [Abstract][Full Text] [Related]
17. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
[TBL] [Abstract][Full Text] [Related]
18. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
Zhu Y; Zhou J; Zhu L; Hu W; Liu B; Xie L
Hum Vaccin Immunother; 2022 Nov; 18(5):2060019. PubMed ID: 35468048
[TBL] [Abstract][Full Text] [Related]
19. Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A; Watkins R; Vilgelm AE
Front Immunol; 2021; 12():690499. PubMed ID: 34140957
[TBL] [Abstract][Full Text] [Related]
20. Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.
Li J; Liu H; Li Y; Li J; Shen L; Long W; Yang C; Xu H; Xi W; Cai R; Feng W
Trials; 2022 Jan; 23(1):29. PubMed ID: 35012634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]